FindTrial
Sign In

COMPARISION OF QUALITY OF LIFE AFTER injecting 2 different steroids in patient with low back pain

COMPARISION OF QUALITY OF LIFE AFTER METHYLPREDNISOLONE SUCCINATE VERSUS TRIAMCINOLONE ACETONIDE CAUDAL EPIDURAL INJECTION IN PATIENTS WITH PROLAPSED INTERVERTEBRAL DISC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/054686
Enrollment
202
Registered
2023-07-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M518- Other thoracic, thoracolumbar andlumbosacral intervertebral disc disorders

Interventions

Intervention1: TRIAMCINOLONE ACETONIDE: CAUDAL EPIDURAL INJECTION TRIAMCINOLONE ACETONIDE 40MG + 0.25% BUPIVACAINE + 0.9% NORMAL SALINE TO MAKE IT MAXIMUM OF 20ML VIA CAUDAL EPIDURAL ROUTE SINGLE INJ

Sponsors

AIIMs Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 18 TO 60 YEARS OF AGE WITH LOW BACK PAIN MRI FINDING SHOWS PIVD L4L5 OR L5S1 OR BOTH PATIENT WITH PIVD REFRACTORY TO PHARMACOLOGICAL TREATMENT FOR 1 MONTH ( NRS >6/10 AFTER 1MONTH OF THERAPY) LUMBAR CANAL DIAMETER >7MM CENTRAL AND PARACENTRAL DISC PROLAPSE

Exclusion criteria

Exclusion criteria: PAST HISTORY OF SPINAL INJECTION OR CAUDAL EPIDURAL IN 6 MONTHS PRIOR HISTORY OF SURGERY IN LOWER BACK DEFORMITIES IN SPINE BMI >35 PREGNANCY OTHER CAUSES OF LOWER BACK PAIN PATIENT WITH BLEEDING DISORDER AND INFECTION OVER INJECTION SITE PATIENT WITH CAUDA EQUINA SYNDROME NEUROLOGICAL DEFICIT DUE TO SPINAL CORD COMPRESSION UNCONTROLLED DIABETES OR HYPERTENSION

Design outcomes

Primary

MeasureTime frame
1.Comparison of quality of life parameter using Roland Morris questionnaire in both groups at baseline and at interval of 1 and 3 months 2.To assess and compare the improvement in pain using NRS scale between 2 groups at baseline and at interval of 1 and 3 months of epidural injection Timepoint: BEFORE PROCEDURE 1 AND 3 MONTHS—

Secondary

MeasureTime frame
IMPROVEMENT IN NEUROPATHIC PAIN USING DN4 QUESTIONNAIRE STRESS AND ANXEITY LEVEL USING DASS 21 QUESTIONNAIRE AND ACECLOFENAC CONSUMPTION AT BASELINE 1 AND 3 MONTHTimepoint: IMPROVEMENT IN NEUROPATHIC PAIN USING DN4 QUESTIONNAIRE STRESS AND ANXEITY LEVEL USING DASS 21 QUESTIONNAIRE AND ACECLOFENAC CONSUMPTION AT BASELINE 1 AND 3 MONTH—

Countries

India

Contacts

Public ContactSarankumar G

All india institute of medical science

sarankumarerk2013@gmail.com6374522681

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026